Bayer, Versant close $225m Series A to launch stem cell company

December 12, 2016 By Sarah Faulkner

Bayer (ETR:BAYN) and Versant Ventures said today that the 2 groups closed a $225 million Series A financing round to launch BlueRock Therapeutics, a regenerative medicine company focused on developing induced pluripotent stem cell therapies. The funds are estimated to support the company for 4 years as it advances cell therapy clinical programs for cardiovascular and degenerative diseases.

“Accessing cell based therapies is part of Bayer’s strategy. We are launching this enterprise to develop transformative and curative therapies for patients based on the latest stem cell technology,” Kemal Malik, member of the Board of Management of Bayer AG, said in prepared remarks. “We have partnered with Versant Ventures to build a leading player in this field by securing exclusive access to these breakthrough technologies for BlueRock Therapeutics.”

Get the full story at our sister site, Drug Delivery Business News.

Integer reports mixed results in Q3
Integer Holdings (NYSE:ITGR) today reported third-quarter earnings that beat the Wall Street consensus forecast on earnings — but not on revenue. The Plano, Texas–based medical device contract manufacturing giant reported profits of $30.3 million, or 92¢ per share, off sales of $236 million for the quarter ended Oct. 2, 2020, for steady bottom-line and a top-line… […]
Dunlee replacement CT tubes win FDA clearance
Dunlee this week announced that its DA200P40+LMB CT replacement tube received FDA clearance. The replacement CT tubes feature CoolGlide technology and is an alternative to liquid metal bearing replacement CT tubes for GE Revolution Evo and Optima 660 CT scanners. Liquid metal bearing in CT tubes doesn’t create friction, which results in less wear, according… […]
Cadence adds Class 8 cleanroom at Virginia HQ
Contract manufacturer Cadence announced the addition of an ISO Class 8 cleanroom at its headquarters located in Staunton, Va. The new cleanroom will be used for the development and manufacturing of novel medical devices. “We are excited about expanding the capabilities at our Virginia facility,” said Cadence operations VP Chris McHugh in a news release.… […]
Medidata acquires MC10’s digital biomarker business
Medidata announced that it has acquired the digital biomarker business of MC10 to help integrate data from wearable sensors — including clinical-grade metrics — so customers may make clinical trials virtual. MC10’s offerings will bring novel clinical analytics and biosensor capabilities to Medidata’s existing patient cloud solutions in ePRO (patient-reported outcomes), eCOA (clinical outcome assessments)… […]
What drugmakers need to know about analytical testing for drug-device combinations
Pharmaceutical manufacturers need to understand the compatibility and performance of the primary packaging system with both the drug and its delivery system. Jennifer Riter, West Pharmaceutical As more pharmaceutical manufacturers develop combination products, they identify new and complex interactions among packaging components and delivery systems. Understanding this interplay is critical to developing a successful drug-device… […]
TE Connectivity beats The Street on lower Q4 sales
TE Connectivity (NYSE:TEL) today reported its healthcare sales were down by $16 million for the fourth quarter of its 2020 fiscal year. Schaffhausen, Switzerland-based TE Connectivity reported overall sales of $3.261 billion for the quarter ended Sept. 25, 2020, down 8.7% from the same quarter one year ago. Adjusted to exclude one-time items, earnings per share… […]
3M slightly down despite Street-beating Q3
3M (NYSE:MMM) shares took a slight dip today on third-quarter results that finished ahead of the consensus forecast. The St. Paul, Minn.-based company posted profits of $1.4 billion, or $2.43 per share, on sales of $8.4 billion for the three months ended Sept. 30, 2020, for a -10.7% bottom-line slide on sales growth of 4.5%. Adjusted… […]
Dynocardia lands spot in Dassault Systèmes startup accelerator
Medtech startup Dynocardia, which is developing a continuous, non-invasive blood pressure (BP) measuring device, announced today that it has been selected for the Dassault Systèmes 3DExperience Lab accelerator program. Participation in the accelerator could help Dynocardia expedite the development of its ViTrack technology, which the company touts as a solution to problems stemming from inaccurate,… […]
The 12 largest medtech employers of 2020 – and what their employees really think
Employees of the 12 largest medtech employers are proud of working on life-saving products with added benefits due to the COVID-19 pandemic, but also reported frustration with big corporate bureaucracy. That was one major takeaway as Medical Design & Outsourcing compiled some current and former employee reviews posted on Glassdoor. The companies are the largest… […]
Integer gets $28M from long-running patent spat
Integer Holdings (NYSE:ITGR) said today it has received a payment of approximately $28 million resulting from its July 2020 patent victory against AVX. An appeals court upheld a $22.2 million jury verdict in July in the long-standing patent spat between Integer, formerly known as Greatbatch, and AVX, now part of Kyocera. Integer said it has applied… […]
Cleveland Clinic study finds no advantage to robotic hernia surgery
A small study out of the Cleveland Clinic has found no apparent clinical benefit to the use of surgical robotics in abdominal hernia repairs using intraperitoneal mesh. Laparoscopic intraperitoneal mesh placement is notoriously painful in the early postoperative period, and rates of chronic pain, bulging, with patient dissatisfaction as high as 25%, the researchers noted.… […]